DexCom, Inc. (DXCM)
| Market Cap | 30.49B +27.8% |
| Revenue (ttm) | 5.10B +13.0% |
| Net Income | 991.00M +37.5% |
| EPS | 2.55 +41.9% |
| Shares Out | 372.95M |
| PE Ratio | 32.06 |
| Forward PE | 27.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 125,880 |
| Open | 82.73 |
| Previous Close | 84.46 |
| Day's Range | 81.75 - 82.73 |
| 52-Week Range | 54.11 - 92.59 |
| Beta | 1.44 |
| Analysts | Strong Buy |
| Price Target | 98.15 (+20.06%) |
| Earnings Date | Oct 29, 2026 |
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin;... [Read more]
Financial Performance
In 2025, DexCom's revenue was $4.66 billion, an increase of 15.60% compared to the previous year's $4.03 billion. Earnings were $836.30 million, an increase of 45.14%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for DXCM stock is "Strong Buy." The 12-month stock price target is $98.15, which is an increase of 20.06% from the latest price.
News
DexCom launches ‘A Letter to Diabetes’ campaign
DexCom (DXCM) launched A Letter to Diabetes in honor of National Diabetes Awareness Month and World Diabetes Day, creating a platform for people around the world to put into words…
Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today launched A Letter to Diabetes in honor of National Diabetes Awareness Month and World Diabetes D...
DexCom price target raised to $85 from $82 at JPMorgan
JPMorgan raised the firm’s price target on DexCom (DXCM) to $85 from $82 and keeps a Neutral rating on the shares.
DexCom price target raised to $97 from $94 at Raymond James
Raymond James raised the firm’s price target on DexCom (DXCM) to $97 from $94 and keeps a Strong Buy rating on the shares. DexCom’s U.S. sales growth accelerated in Q3,…
DexCom price target raised to $93 from $82 at StoneX
StoneX raised the firm’s price target on DexCom (DXCM) to $93 from $82 and keeps a Buy rating on the shares.
DexCom price target raised to $107 from $102 at UBS
UBS raised the firm’s price target on DexCom (DXCM) to $107 from $102 and keeps a Buy rating on the shares.
DexCom price target raised to $97 from $90 at Canaccord
Canaccord raised the firm’s price target on DexCom (DXCM) to $97 from $90 and keeps a Buy rating on the shares. The firm updated its model following Q3 results which…
DexCom price target raised to $120 from $115 at Barclays
Barclays raised the firm’s price target on DexCom (DXCM) to $120 from $115 and keeps an Overweight rating on the shares. The firm views the company’s Q3 report as solid.
DexCom announces $1B share repurchase program
On October 29, Dexcom (DXCM) announced that its Board of Directors authorized and approved a share repurchase program of up to $1B of Dexcom’s outstanding common stock, with a repurchase…
DexCom narrows FY26 revenue view to $5.20B-$5.25B, consensus $5.23B.
Prior guidance was $5.15B-$5.25B. Sees FY26: Non-GAAP Gross Profit Margin of approximately 64%, Non-GAAP Operating Margin of approximately 24%.
DexCom reports Q3 EPS 73c, consensus 67c
Reports Q3 revenue $1.34B, consensus $1.33B.U.S. revenue grew 14% and international revenue grew 5% on a reported basis and 5% on an organic1 basis, all on a year-over-year basis. “This…
DexCom Earnings Call Transcript: Q3 2026
Q3 revenue grew 11%, with U.S. share gains, stronger margins and near-record patient starts. FY revenue guidance rose to $5.20B–$5.25B; broader access, product launches and G7 15 Day adoption underpin the outlook.
DexCom Earnings release: Q3 2026
DexCom released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
DexCom Slides: Q3 2026
DexCom has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
DexCom Quarterly report: Q3 2026
DexCom has published its Q3 2026 quarterly earnings report on October 29, 2026.
Dexcom Reports Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2026 Financial Results.
DexCom announces Dexcom G7 15 Day CGM to launch in Canada
DexCom (DXCM) announced that the Dexcom G7 15 Day Continuous Glucose Monitoring System, CGM, will be available in Canada beginning next month for adults 18 years and older living with…
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) w...
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, regardless of insulin dependence. We also report on a positive trial of a J&J pil...
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
DexCom shares jump 2.4% premarket after study results published in NEJM
DexCom (DXCM) on Wednesday announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine, providing rigorous evidence of the s...
Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published...
DexCom price target raised to $100 from $95 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on DexCom (DXCM) to $100 from $95 and keeps an Outperform rating on the shares. The firm adjusted targets in the…